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Understanding the mode of action for lipoxygenase (LOX) inhibitors is critical to determining their efﬁ-
cacy in the cell. The pseudoperoxidase assay is an important tool for establishing if a LOX inhibitor is
reductive in nature, however, there have been difﬁculties identifying the proper conditions for each of
the many human LOX isozymes. In the current paper, both the 234 nM decomposition (UV) and iron-
xylenol orange (XO) assays are shown to be effective methods of detecting pseudoperoxidase activity
for 5-LOX, 12-LOX, 15-LOX-1 and 15-LOX-2, but only if 13-(S)-HPODE is used as the hydroperoxide sub-
strate. The AA products, 12-(S)-HPETE and 15-(S)-HPETE, are not consistent hydroperoxide substrates
since they undergo a competing transformation to the di-HETE products. Utilizing the above conditions,
the selective 12-LOX and 15-LOX-1 inhibitors, probes for diabetes, stroke and asthma, are characterized
for their inhibitory nature. Interestingly, ascorbic acid also supports the pseudoperoxidase assay, suggest-
ing that it may have a role in maintaining the inactive ferrous form of LOX in the cell. In addition, it is
observed that nordihydroguaiaretic acid (NDGA), a known reductive LOX inhibitor, appears to generate
radical species during the pseudoperoxidase assay, which are potent inhibitors against the human LOX
isozymes, producing a negative pseudoperoxidase result. Therefore, inhibitors that do not support the
pseudoperoxidase assay with the human LOX isozymes, should also be investigated for rapid inactivation,
to clarify the negative pseudoperoxidase result.
 2013 The Authors. Published by Elsevier Ltd.Open access under CC BY-NC-ND license.1. Introduction non-heme iron center to incorporate molecular oxygen into a vari-The inﬂammatory response in humans is regulated by fatty acid
signaling cascades, which are initiated by the oxidation of polyun-
saturated fatty acids. Three classes of enzymes catalyze this
oxidation: cyclooxygenase (COX);1 cytochrome P450;2 and lipoxy-
genase3 the latter of which is the focus of this study. Lipoxygenases
(LOX) are a family of iron containing metalloenzymes that utilize aety of fatty acids. There are three main LOXs of pharmacological
importance, 5-LOX, 12-LOX and 15-LOX. They are named according
to their oxygenation position on arachidonic acid (AA),4 generating
the hydroperoxyeicosatetraenoic acid (HPETE) product.5 HPETEs
are responsible for maintaining the homeostasis of the inﬂamma-
tory response,6 and have also been implicated in many human dis-
eases, such as asthma,7 psoriasis,8 atherosclerosis,9 Abbreviations
cancer,10 heart disease 11,12 and diabetes,13 to name a few.
Due to the important role LOX plays in human disease, numer-
ous inhibitors for LOX have been reported,14–28 which can be gen-
erally classiﬁed into three categories. There are reductive
inhibitors (such as Zileuton,21,22 BWb70c,19,20,26 NDGA,27,28 chela-
tive (such as compound 1 29) and competitive/mixed inhibitors
(such as compound 2,30)) shown in Figure 1. Nevertheless, only
one compound has been approved as a drug, Zileuton,21,22 a potent
and selective 5-LOX inhibitor.20,23 It contains an N-hydroxyurea
moiety, which chelates to the active ferric ion and reduces it to
the inactive ferrous ion.23–25 Many other reductive inhibitors of
LOX have been found, such as N-hydroxyureas, hydroxybenzofu-
rans, hydroxamic acids, hydroxylamines, and catechols,18–20,26
indicating the ease of which LOX isozymes can be inhibited in this
manner. However, it is challenging to determine whether a
particular inhibitor of LOX is reductive because it is difﬁcult to
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Figure 1. Classiﬁcations of general LOX inhibitors.
Figure 2. The LOX pseudoperoxidase reaction scheme.
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ization of the active site iron by electron paramagnetic resonance
(EPR) is not possible. Interestingly, Zileuton and other hydroxamic
acids were initially designed to chelate the iron center of LOX,21,25
but it was later determined, using the UV pseudoperoxidase assay,
that Zileuton also reduced the active site iron of 5-LOX.18 Nord-
ihydroguaiaretic acid (NDGA), found in the Larrea tridentata plant,
is another example of a non-speciﬁc LOX inhibitor, which pos-
sesses a dual mode of inhibition 27,31,32. NDGA contains a catechol
moiety, which binds to the active site ferric ion, but it also reduces
it to the ferrous ion, with the concomitant oxidation of the catechol
moiety to the semiquinone. This reactivity is also seen with the
non-heme iron enzyme, catechol dioxygenase, whose catechol sub-
strate is activated to the semiquinone by the active site ferric ion
for oxidation by molecular oxygen.32–34
Considering that direct detection of the reduced active site iron
by EPR is not practical for many human LOX isozymes, the typical
method for determining whether an inhibitor is reductive in nature
is the pseudoperoxidase reaction. This reaction follows the reduc-
tion of the fatty acid hydroperoxide product by the ferrous ion to
the alkoxyl radical, generating the active ferric form of LOX
(Fig. 2). However, for this process to be catalytic, a reducing inhib-
itor is required to reduce the ferric ion back to its ferrous form. This
cycling results in the degradation of both the hydroperoxide prod-
uct and the reducing inhibitor to their corresponding radicals. The
reaction is typically witnessed by the reduced absorbance at
234 nM,35–37 due to the decomposition of the resulting alkoxyl rad-
ical, triggering a loss in the conjugation of the hydroperoxide prod-
uct. However, this assay is not without its difﬁculties when
Riendeau and coworkers observed that NDGA and 13-(S)-HPODE
did not support the pseudoperoxidase assay with 5-LOX.37 An
alternative method for researchers to investigate reductive inhibi-
tors is to monitor their ability to quench the free radical of 1,1-di-
phenyl-2-picrylhydrazyl (DPPH), but this method is not reliable for
predicting the reductive activity of LOX inhibitors. DPPH is consid-ered a general indicator of the cellular reduction potential,38,39
which is distinct from the reduction potential of the various LOX
isozymes. Alternatively, several methods can be employed
to detect the loss of the hydroperoxide product directly, such as io-
dine oxidation,40 radiolabeling,41 thiobarbituric acid (TBA),42 enzy-
matic oxidation of dyes,43 and coupled oxidation of NADH.44
Unfortunately, these assays are tedious and subject to various con-
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the ﬂuorescent indicator, diphenyl-1-pyrenylphosphine (DPPP),45
and the visible indicator, iron-xylenol orange (XO),46,47 both of
which are oxidized by the hydroperoxy-lipids, changing their spec-
troscopic properties. These methods are robust and have been suc-
cessfully utilized for high-throughput inhibitor screening of LOX
inhibitors.29,30,45,48
Given the need for a robust pseudoperoxidase procedure to
determine the inhibitory mechanism of reducing inhibitors, we
have utilized both the conjugated diene decomposition (UV) and
iron-xylenol orange (XO) pseudoperoxidase assays to determine
the best hydroperoxides for the pseudoperoxidase reaction against
the human isozymes, 5-LOX, 12-LOX, 15-LOX-1 and 15-LOX-2. In
addition, the reductive nature of a variety of disease related LOX
inhibitors were determined utilizing the aforementioned UV and
XO assays.
2. Materials and methods
2.1. Materials
All commercial fatty acids (Sigma–Aldrich Chemical Company,
and NuCheck) were stored at 80 C for a maximum of 6 months.
LOX products were generated by reacting substrate with the
appropriate LOX isozyme (13-(S)-HPODE from soybean LOX-1
and LA, 15-(S)-HPETE from 15-LOX-2 and AA, 12-(S)-HPETE from
12-LOX and AA). Product generation was performed as follows. A
2 L solution of 50–100 lM substrate in the appropriate buffer
(50 mM Borate pH 9.2 for soybean LOX-1, 25 mM HEPES pH 7.5
for 15-LOX-2 and 25 mM HEPES pH 8 for 12-LOX) was run to com-
pletion, quenched with 10 mL acetic acid, extracted three times
with dichloromethane, evaporated to dryness, and reconstituted
in MeOH for HPLC puriﬁcation. The products were HPLC puriﬁed
using an isocratic elution of 55% acetonitrile: 45% H2O: 0.1% acetic
acid. All products were tested with enzyme to show that no resid-
ual substrate was present and subjected to analytical HPLC to test
for purity. Zileuton, BWb70c and NDGA were purchased from Sig-
ma/Aldrich Chemicals. The inhibitors, compounds 1, and 2 were
previously characterized and kindly provided by the NIH Chemical
Genomics Center (NCGC). All other chemicals were reagent grade
or better and were used without further puriﬁcation.2.2. Overexpression and puriﬁcation of 5-human lipoxygenase,
12-human lipoxygenase, and the 15-human lipoxygenases
Human reticulocyte 15-lipoxygenase-1 (15-LOX-1)49 and
human platelet 12-lipoxygenase (12-LOX)49 and human prostate
epithelial 15-lipoxygenase-2 (15-LOX-2)50 were expressed as N-
terminally, His6-tagged proteins and puriﬁed to greater than 90%
purity. Human leukocyte 5-lipoxygenase was expressed as a non-
tagged protein and used as a crude ammonium sulfate protein frac-
tion, as published previously.51
2.3. Evaluation of hydroperoxides as pseudoperoxidase
substrates
The ability of various HPETEs to serve as substrates to the pseu-
doperoxidase activity was investigated with 20 lM BWb70c and
the LOX isozymes. Pseudoperoxidase activity measurements were
conducted on a Perkin–Elmer Lambda 40 UV/Vis spectrometer
using a universal assay buffer for all human LOXs screened
(50 mM Sodium Phosphate (pH 7.4), 0.3 mM CaCl2, 0.1 mM EDTA,
and 0.01% Triton X100). The hydroperoxide concentration was
20 lM of 13-(S)-HPODE for all LOX isozymes investigated. How-
ever, in the case of 12-HPETE and 15-HPETE, 20 lM was used for5-LOX and 15-LOX-1, whereas 40 lM was used in the case of 12-
LOX and 15-LOX-2. This higher concentration of hydroperoxide
was due to competing reactions for these two LOX isozymes (vide
infra). The following concentrations of each isozyme were used
(400 nM of 12-LOX, 300 nM of 15-LOX-1, 2 lM of 15-LOX-2) in
2 mL of buffer, on an oscillating shaker (22 C). The reaction was
initiated by addition of 20 lM BWb70c, a known reductive inhibi-
tor. The reaction was incubated for 30 min and quenched with two
parts of the iron-xylenol orange solution (25 mM H2SO4, 100 mM
xylenol orange, and 250 mM ferrous sulfate, solubilized in 90:10
methanol/water).46,47 In order to determine if any competing reac-
tions degraded the hydroperoxide, the hydroperoxide stability (i.e.,
maximal absorption at 590 nM) was determined through the use of
two controls. The ﬁrst control measured an inhibitor/hydroperox-
ide solution with iron-xylenol orange added, to account for any
degradation of the hydroperoxide by the inhibitor. The second con-
trol measured an enzyme/hydroperoxide solution with iron-xyle-
nol orange added, to account for any breakdown of the
hydroperoxide by the LOX isozyme, without the inhibitor present.
These two controls allowed for the determination of the back-
ground percentage, which was subsequently subtracted from the
measured percentage. In all cases, the inhibitors did not degrade
a signiﬁcant amount of hydroperoxide product, however, some
LOX isozymes did degrade 12-(S)-HPETE and 15-(S)-HPETE by
increasing their absorbance at 280 nM, presumably through con-
verting the HPETEs to di-HETEs. Due to this slow consumption of
hydroperoxide by 12-LOX and 15-LOX-2, higher concentrations
of hydroperoxides (40 lM) were required to ensure a sufﬁcient
rate of the pseudoperoxidase reaction, relative to that of the afore-
mentioned background reactions. In all assays, the primary absorp-
tion peaks for the hydroperoxide lipids and their oxidized
metabolites were conﬁned to the UV region, resulting in no overlap
between their absorption bands and that of the 590 nM oxidized
iron-xylenol orange product. Controls to establish the endpoint
of the pseudoperoxidase reaction (i.e., 100% degradation of the
hydroperoxide) were conducted by measuring an iron-xylenol or-
ange solution with enzyme and inhibitor, but no hydroperoxide
added. Given the large error for these results, 20% or less, a positive
result for pseudoperoxidase activity, after the subtraction of con-
trol rates, was considered a loss of greater than 45% absorption
at 590 nM in 30 min. The amount of enzyme varied for each LOX
isozyme, so this minimal level of detection corresponds to approx-
imately 1.3 mol/min/mol for 12-LOX, 1.5 mol/min/mol for 15-LOX-
1 and 0.25 mol/min/mol for 15-LOX-2.
2.4. Iron-xylenol orange pseudoperoxidase inhibitor assay
The reductive properties of the inhibitors were determined by
monitoring the pseudoperoxidase activity of lipoxygenase in the
presence of 40 lM inhibitor and 20 lM 13-(S)-HPODE. Increased
concentrations of inhibitors were used in this assay to drive the
reaction to completion. Pseudoperoxidase activity measurements
were conducted as described above. All inhibitors were ran alone
with 13-(S)-HPODE to account for direct breakdown of 13-(S)-
HPODE, and to account for absorbance changes from individual
inhibitors. The control inhibitors for this assay were Zileuton and
BWb70c, known reductive inhibitors.
2.5. UV pseudoperoxidase activity assay
The pseudoperoxidase activity rates were determined with
BWb70c as the reducing inhibitor, 13-(S)-HPODE as the oxidizing
product and the following isozymes; 12-LOX, 15-LOX-1 and 15-
LOX-2. Activity for all isozymes was determined by monitoring
the decrease at 234 nM (product degradation) in buffer (50 mM
Sodium Phosphate (pH 7.4), 0.3 mM CaCl2, 0.1 mM EDTA, 0.01%
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Lambda 40 UV/Vis spectrometer. The following concentrations of
each isozyme were used (400 nM of 12-LOX, 300 nM of 15-LOX-
1, 2 lM of 15-LOX-2), in 2 mL of buffer and constantly stirred with
a rotating stir bar (22 C). The reaction was initiated by addition of
20 lM inhibitor (at a 1:1 ratio to product), and the initial rate re-
corded. The percent consumption of 13-(S)-HPODE was recorded
for each of the isozymes, with a loss of product less than 35% not
being considered as signiﬁcant activity. Individual controls were
conducted with inhibitor alone with product and enzyme alone
with product. These negative controls established the baseline for
the assay, reﬂecting non-pseudoperoxidase dependent hydroper-
oxy product decomposition.
2.6. Residual oxygenase activity after the pseudoperoxidase
reaction
To evaluate whether inactivation was occurring as a result of
pseudoperoxidase cycling, the LOX residual activity was measured
after a set amount of pseudoperoxidase turnover was completed.
Activity is characterized by direct measurement of the product for-
mation with the increase of absorbance at 234 nM using a Perkin–
Elmer Lambda 40 UV/Vis spectrometer. All human isozymes uti-
lized the same buffer (50 mM Sodium Phosphate (pH 7.4),
0.3 mM CaCl2, 0.1 mM EDTA, and 0.01% Triton X100) and were con-
stantly stirred with a rotating stir bar in 2 mL of buffer (22 C).
Pseudoperoxidase reactions were initiated as described above, ex-
cept in the case of 15-LOX-1, where compound 2 (Fig. 1) was
screened at lower inhibitor concentration (10 lM), due to the high
potency of this inhibitor (compound 5 in our previous publica-
tion,30 IC50 = 19 nM)). Oxygenase activity was evaluated 2 min post
initiation of the pseudoperoxidase assay by the addition of 20 lM
AA to the reaction mixture. This time interval was determined to
be sufﬁcient to inactivate the isozymes with NDGA. Residual activ-
ity was determined by comparing the initial rates with inhibitor
and 13-(S)-HPODE versus inhibitor alone, since the inhibitor itself
lowers the rate of the oxygenation.
3. Results and discussion
3.1. Evaluation of hydroperoxides as pseudoperoxidase
substrates
To further understand the pseudoperoxidase activity of the var-
ious LOXs, the primary products from AA and LA, 13-(S)-HPODE,
12-(S)-HPETE and 15-(S)-HPETE, were screened to determine if
they were substrates for the XO pseudoperoxidase assay (Table 1).
It was observed that 13-(S)-HPODE was the most effective sub-
strate for all the LOX isozymes tested, as seen by the large con-
sumption of the hydroperoxide product. Interestingly, 12-(S)-
HPETE and 15-(S)-HPETE were not effective pseudoperoxidase
substrates, especially with 12-LOX and 15-LOX-2. We attribute thisTable 1
Product decomposition percentages with the XO pseudoperoxidase assaya
13-(S)-HPODE (%) 12-(S)-HPETE (%) 15-(S)-HPETE (%)
5-LOX 75b 80 100
12-LOX 50 <20c <20c
15-LOX-1 100 100 75
15-LOX-2 100 50c 50c
a The assay was conducted over a 30 min turnover period, using 20 lM hydro-
peroxide and 20 lM BWb70c within 50 mM Sodium Phosphate (pH 7.4), 0.3 mM
CaCl2, 0.1 mM EDTA, and 0.01% Triton X100.
b All values had an error of 20% or less.
c Due to the oxygenation reaction, 40 lM hydroperoxide was used in these
reactions.to the fact that these LOX products can also be oxygenation sub-
strates, resulting in doubly oxygenated products (i.e., di-HETEs).
For both 12-LOX and 15-LOX-2, the oxygenation rates were com-
parable to the pseudoperoxidase rates, making measurements dif-
ﬁcult. For these two isozymes, the HPETE concentration was
increased to 40 lM to obtain more reliable data. In the case of
15-LOX-2, this increase in concentration allowed for a measurable
pseudoperoxidase rate, above that of the oxygenation rate. How-
ever, these conditions did not allow for measurable pseudoperox-
idase rates for 12-LOX. Therefore, 13-(S)-HPODE is the most
reliable substrate for all of the LOX isozymes with the XO pseudo-
peroxidase assay.
3.2. Iron-xylenol orange pseudoperoxidase inhibitor assay
LOX inhibitors were screened against 5-LOX, 12-LOX, 15-LOX-1
and 15-LOX-2 to evaluate their ability to reduce the active ferric
form of the isozyme. Initially the iron-xylenol orange (XO) pseudo-
peroxidase assay with 13-(S)-HPODE was utilized with the well-
characterized reductive inhibitors, Zileuton and BWB70c (Fig. 1).
These two inhibitors were active against all isozymes screened,
indicating that each isozyme is capable of oxidizing these two
inhibitors and reducing 13-(S)-HPODE to complete the pseudoper-
oxidase cycle (Fig. 2 and Table 2). 5-LOX and 15-LOX-1 displayed
the most consistent pseudoperoxidase activities, displaying the
greatest total consumption of 13-(S)-HPODE. Compound 1, does
not support the assay, indicating that it is not a reductive inhibi-
tor.29 Compound 1 is a potent and selective 12-LOX inhibitor that
is currently being investigated for its activity against diabetes
and heart disease.29 It has been proposed that compound 1 che-
lates the active site iron, similarly to Zileuton, however, it was
not known at the time whether it was reductive in nature, since
EPR spectroscopy was not possible. The current data indicates that
compound 1 is distinct from Zileuton in that it does not reduce the
ferric ion to the inactive ferrous state. The 15-LOX-1 inhibitor,
compound 2, also does not display reductive LOX isozyme activity.
Compound 2 is a potential therapeutic for stroke and these results
are consistent with its inability to reduce the standard free radical
1,1-diphenyl-2-picrylhydrazyl (DPPH).30 Interestingly, ascorbic
acid (Fig. 1), a known reductant with high concentrations in the
cell, also supported the XO pseudoperoxidase assay. This is consis-
tent with its chelative structure and reductive nature and suggests
that ascorbic acid may facilitate the conversion of LOX isozymes to
their inactive ferrous form in the cell. NDGA, however, did not sup-
port the XO pseudoperoxidase assay with any of the LOX isozymes.
These results are inconsistent with our previous work, which dem-
onstrated that NDGA and a variety of its derivatives displayed
reductive activity against soybean LOX-1.27 These conﬂicting data
suggested that the human LOX isozymes may interact differently
with NDGA than soybean LOX-1, as previously seen with 5-LOX
(vide infra).37Table 2
XO pseudoperoxidase assay percent conversion results of LOX isozymes with various
inhibitorsa
Compound 5-LOX (%) 12-LOX (%) 15-LOX-1 (%) 15-LOX-2 (%)
Zileuton 100b 50 100 100
BWb70C 100 50 100 100
NDGA 0 0 0 0
Ascorbic acid 50 50 85 75
1 0 0 0 0
2 0 0 0 0
a The assay was conducted over a 30 min turnover period, using 20 lM 13-(S)-
HPODE and 40 lM inhibitor within 50 mM Sodium Phosphate (pH 7.4), 0.3 mM
CaCl2, 0.1 mM EDTA, and 0.01% Triton X100.
b All values had an error of 20% or less.
Table 3
Rate comparison of LOX isozymes with the UV pseudoperoxidase assaya
12-LOX 15-LOX-1 15-LOX-2
mmax (mol/s/mol) 0.14 ± 0.01 3.3 ± 0.06 0.013 ± 0.001
Conversion (%) 40% 50% 40%
a The assays were conducted using 20 lM 13-(S)-HPODE and 20 lM BWb70C
within 50 mM Sodium Phosphate (pH 7.4), 0.3 mM CaCl2, 0.1 mM EDTA, and 0.01%
Triton X100. The percent conversion was evaluated over a 30 min time period.
Table 4
Residual activity after completion of the UV pseudoperoxidase assaya
Enzyme 13-(S)-
HPODE/
NDGA (%)
13-(S)-
HPODE/
BWb70c
(%)
13-(S)-HPODE/
compound #1
(%)
13-(S)-HPODE/
compound #2
(%)
12-LOX 0b 80 100 100
15-LOX-1 0 50 100 100
15-LOX-2 10 50 100 100
a Enzyme was incubated for 2 min in 20 lM 13-(S)-HPODE and 20 lM inhibitor
within 50 mM Sodium Phosphate (pH 7.4), 0.3 mM CaCl2, 0.1 mM EDTA, and 0.01%
Triton X100. Residual activity was measured by addition of 20 lM AA, following the
increase in absorbance at 234 nM.
b All values had an error of 20% or less.
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As mentioned above, an alternative method to the XO pseudo-
peroxidase assay is to measure the decomposition of the hydroper-
oxide by monitoring the decrease at 234 nM. Unlike the XO
pseudoperoxidase assay, in which the signal is produced by the
hydroperoxide reacting directly with the ferrous xylenol orange
complex, the UV pseudoperoxidase assay follows the decrease in
absorbance (234 nM), which is a secondary decomposition of the
alkoxyl radical after the hydroperoxide oxidation of the ferrous
center.35,37 Even though the UV pseudoperoxidase assay does not
directly measure the decomposition of the hydroperoxide, it does
have the advantage of being a continuous assay, allowing for the
rate determination of pseudoperoxidase activities amongst the
various human isozymes. Utilizing this method, BWb70c was
screened against the lipoxygenase isozymes and observed that
15-LOX-1 had the greatest mmax at 20 lM 13-(S)-HPODE, with a
rate of 3.3 ± 0.06 mol/s/mol, 20 times the velocity of 12-LOX,
and 250 times that of 15-LOX-2 (Table 3). NDGA, however, did
not display UV pseudoperoxidase activity with any of these three
LOX isozymes, consistent with the results of the XO pseudoperox-
idase assay. It should be noted that the low percent decomposition
of 13-(S)-HPODE with the UV assay is due to the fact that this assay
is detecting the secondary decomposition of the alkoxyl radical,
not the primary decomposition of the hydroperoxide, as seen in
the XO assay.3.4. Residual oxygenase activity after the pseudoperoxidase
reaction
Previous to this publication, NDGA was shown to be a reductive
inhibitor against soybean LOX-1,27 which was consistent with its
catechol structure, but it was inactive in the 5-LOX pseudoperoxi-
dase assay.37 In this investigation, NDGA also did not support the
pseudoperoxidase assay with 5-LOX, nor with 12-LOX, 15-LOX-1
and 15-LOX-2. A possible explanation for this lack of pseudoperox-
idase activity by NDGA could be due to its radical chemistry and
the auto-inactivation of the human LOX isozymes. It is known that
human LOX isozymes auto-inactivate,52 presumably through oxi-
dation of active site residues by radical intermediates generated
in the catalytic process, but it has not been proven conclusively.53
Considering that the pseudoperoxidase assay generates both
hydroperoxide and inhibitor radicals (the one electron reduced
hydroperoxide and the one electron oxidized inhibitor, Fig. 2) it
is possible that either radical could inactivate LOX. Therefore, the
activity of the LOX isozymes were determined by adding AA, after
a signiﬁcant amount of 13-(S)-HPODE and reducing inhibitor were
consumed via the pseudoperoxidase activity, and measuring the
residual LOX activity (Table 4). By this method, LOX treated with
a BWB70c/13-(S)-HPODE mixture showed signiﬁcant activity after
the pseudoperoxidase assay, relative to BWb70c alone. Note that
the addition of BWB70c does inhibit the enzyme, but enough resid-
ual activity is observed to establish the relative activity of the LOX
isozyme with and without product present. The competitive inhib-
itors, compounds 1 and 2, also retained residual activity, whichwould be expected from non-reducing inhibitors. In contrast, it
was observed that 12-LOX, 15-LOX-1 and 15-LOX-2 did not dem-
onstrate any oxygenase activity after the pseudoperoxidase turn-
over, when 13-(S)-HPODE and NDGA were added, relative to
NDGA alone. As mentioned above, since the inactivity of LOX ob-
served with 13-(S)-HPODE and NDGA is relative to inhibitor alone,
this lack of activity is not due to the inherent inhibitory activity of
NDGA, but rather is due to the cycling of the pseudoperoxidase
activity with both 13-(S)-HPODE and NDGA being present. This
data is consistent with the inactivation of human LOX isozymes
being due to the presence of NDGA radicals generated through
the pseudoperoxidase activity. This data also indicates that NDGA
is a reducing inhibitor, but that a secondary radical is possibly
the potent inhibitor to the human LOX isozymes. This is consistent
with the work of Riendeau and co-workers, where they observed
that NDGA and 13-(S)-HPODE did not support the pseudoperoxi-
dase assay with 5-LOX.37 We are currently investigating the nature
of this radical and how it inactivates LOX, possibly thru a suicide
inhibitor mechanism. It should be noted that it is unlikely that
the 13-(S)-HPODE radicals, generated during the pseudoperoxidase
activity, inactivate the LOX isozymes. The reaction of various
reductive inhibitors (e.g. BWb70c, Zileuton and ascorbic acid)
and 13-(S)-HPODE do not affect the oxygenase activity of LOX,
even though 13-(S)-HPODE radicals are generated in all of these
reactions.
4. Conclusions
These results demonstrate that both the UV and XO assays are
effective methods of detecting pseudoperoxidase activity for 5-
LOX, 12-LOX, 15-LOX-1 and 15-LOX-2, if 13-(S)-HPODE is used as
the hydroperoxide substrate. The AA products, 12-(S)-HPETE and
15-(S)-HPETE, are not consistent hydroperoxide substrates since
they undergo a competing transformation to the di-HETE products.
These two assays are also effective methods for determining
whether a particular inhibitor is reductive in nature with 5-LOX,
12-LOX, 15-LOX-1 and 15-LOX-2 but there is a caveat. Reductive
inhibitors generate radicals during the pseudoperoxidase assay,
which in the case of NDGA can inactivate human LOX isozymes.
Therefore inhibitors, which do not support the pseudoperoxidase
assay, should also be investigated for rapid inactivation of the
LOX isozyme in order to clarify the negative pseudoperoxidase re-
sult. In comparing the two pseudoperoxidase assays, both do not
measure hydroperoxide levels directly, with the UV assay measur-
ing a side reaction that records only partial degradation of the
hydroperoxide. However, both assays do possess particular advan-
tages, with the XO assay allowing for a high-throughput approach,
as previously reported.46,47 In contrast, the UV assay requires less
set-up time, provides pseudoperoxidase rates and allows for the
determination of enzyme inactivation. Given the advantages and
disadvantages of these two assays, careful thought should be given
E. K. Hoobler et al. / Bioorg. Med. Chem. 21 (2013) 3894–3899 3899when utilizing either method. Finally, the fact that ascorbic acid
supports both the UV and XO pseudoperoxidase assays may imply
wider consequences of the biological reactive state of LOX since
ascorbic acid could help maintain the inactive ferrous form of
LOX isozymes in the cell.
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